NASDAQ:LEXX Lexaria Bioscience 7/12/2024 Earnings Report $0.96 +0.00 (+0.42%) As of 02:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Lexaria Bioscience EPS ResultsActual EPS-$0.13Consensus EPS -$0.09Beat/MissMissed by -$0.04One Year Ago EPSN/ALexaria Bioscience Revenue ResultsActual Revenue$0.08 millionExpected Revenue$0.15 millionBeat/MissMissed by -$70.00 thousandYoY Revenue GrowthN/ALexaria Bioscience Announcement DetailsQuarterDate7/12/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsLexaria Bioscience's next earnings date is estimated for Friday, July 11, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Lexaria Bioscience Earnings HeadlinesLexaria Bioscience announces completion of GLP-1-H25-5 studyJune 12, 2025 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria Attending BIO International ConventionJune 5, 2025 | finanznachrichten.deUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.June 23, 2025 | Stansberry Research (Ad)Lexaria Bioscience prices 2M shares at $1.00 in registered direct offeringApril 26, 2025 | markets.businessinsider.comLexaria provides GLP-1 update following industry developmentsApril 23, 2025 | markets.businessinsider.comRecent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s TechnologyApril 23, 2025 | finance.yahoo.comSee More Lexaria Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexaria Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your email. Email Address About Lexaria BioscienceLexaria Bioscience (NASDAQ:LEXX) operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.View Lexaria Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
